Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327831 · ClinicalTrials.gov registry record · Phase 4
Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses
A Phase 4 study, sponsored by University of California, Irvine.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
NCT03327831 is a Phase 4 study that has completed, run by University of California, Irvine. The registered enrollment target is 30 participants.
The verdict
NCT03327831, a Phase 4 study, has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
Study Summary
Photodynamic therapy is an effective treatment for actinic keratoses. In the United States topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment, and it has traditionally been activated with the use of an in-office artificial light source. This clinical trial seeks to measure the safety and efficacy of using natural sunlight to activate the ALA.
Interventions
- DRUG Aminolevulinic Acid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2015-04 |
| Est. Completion | 2017-07 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03327831
The ClinicalTrials.gov registry entry for NCT03327831 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Aminolevulinic Acid is the first listed.
NCT03327831 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03327831 about?
NCT03327831 is a clinical study titled "Study of Daylight Photodynamic Therapy With Aminolevulinic Acid for Actinic Keratoses". Photodynamic therapy is an effective treatment for actinic keratoses. In the United States topical aminolevulinic acid (ALA) is approved as a photosensitizing agent for this treatment, and it has traditionally been activated with the use of an in-office artificial light source. This clinical trial s...
What is the current status of trial NCT03327831?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2015-04. Estimated completion is 2017-07.
What interventions are being tested in trial NCT03327831?
The interventions under investigation include: Aminolevulinic Acid (DRUG).
Who is sponsoring clinical trial NCT03327831?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.